Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-09-29

AUTHORS

Nobuo Hiwatashi, Yasuo Suzuki, Keiichi Mitsuyama, Akihiro Munakata, Toshifumi Hibi

ABSTRACT

Background and aimsOral mesalazine formulations are effective in the treatment of active ulcerative colitis (UC). It is not clear what induction dose of mesalazine is optimal for treating patients with active UC. We aimed to evaluate the efficacy and safety of 4 versus 2.25 g/day for selected patients with active UC.MethodsA multicenter, randomized, double-blind, parallel-group clinical study in 39 Japanese medical institutions. A total of 123 patients with moderately active UC received 4 g/day (two divided doses) versus 2.25 g/day (three divided doses) for 8 weeks. Primary endpoint was the ulcerative colitis-disease activity index (UC-DAI) score before and after 8 weeks of treatment. The improvement of each individual UC-DAI variable, remission, and efficacy rates were secondary endpoints. Safety was determined by laboratory data, vital signs, subjective symptoms, and objective findings.ResultsPatients receiving 4 g/day achieved a change in UC-DAI score significantly superior to those receiving 2.25 g/day [−3.0 (95% confidence intervals (CI) −3.8 to −2.3) vs. −0.8 (95% CI −1.8 to 0.1), respectively]. There were significant differences in all UC-DAI variables between the groups. Remission rates were 22.0% (4 g/day) and 15.3% (2.25 g/day). The efficacy rate was significantly better with 4 versus 2.25 g/day [76.3 vs. 45.8%, respectively (95% CI 13.8–47.2); P = 0.001]. No difference was seen in adverse events or adverse drug reactions.ConclusionsA dose of 4 g/day was significantly superior to 2.25 g/day in terms of UC-DAI score for patients with moderately active UC. Safety profiles were similar for both doses. More... »

PAGES

46-56

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00535-010-0308-3

DOI

http://dx.doi.org/10.1007/s00535-010-0308-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004696828

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20878425


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents, Non-Steroidal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colitis, Ulcerative", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesalamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tablets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Iwaki Kyoritsu General Hospital, 16 Kusehara, Mimayamachi, Uchigo, 973-8555, Iwaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414859.5", 
          "name": [
            "Department of Gastroenterology, Iwaki Kyoritsu General Hospital, 16 Kusehara, Mimayamachi, Uchigo, 973-8555, Iwaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hiwatashi", 
        "givenName": "Nobuo", 
        "id": "sg:person.0650711113.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650711113.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, 285-8741, Sakura, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265050.4", 
          "name": [
            "Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, 285-8741, Sakura, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Yasuo", 
        "id": "sg:person.011447440744.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011447440744.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410781.b", 
          "name": [
            "Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitsuyama", 
        "givenName": "Keiichi", 
        "id": "sg:person.01233517271.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233517271.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Division of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan", 
          "id": "http://www.grid.ac/institutes/grid.257016.7", 
          "name": [
            "First Division of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Munakata", 
        "givenName": "Akihiro", 
        "id": "sg:person.0711674512.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711674512.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku, 160-8582, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26091.3c", 
          "name": [
            "Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku, 160-8582, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hibi", 
        "givenName": "Toshifumi", 
        "id": "sg:person.01146640377.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146640377.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ajg.2009.727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021345588", 
          "https://doi.org/10.1038/ajg.2009.727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2005.00248.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022975557", 
          "https://doi.org/10.1111/j.1572-0241.2005.00248.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2004.40036.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003586589", 
          "https://doi.org/10.1111/j.1572-0241.2004.40036.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-09-29", 
    "datePublishedReg": "2010-09-29", 
    "description": "Background and aimsOral mesalazine formulations are effective in the treatment of active ulcerative colitis (UC). It is not clear what induction dose of mesalazine is optimal for treating patients with active UC. We aimed to evaluate the efficacy and safety of 4 versus 2.25\u00a0g/day for selected patients with active UC.MethodsA multicenter, randomized, double-blind, parallel-group clinical study in 39 Japanese medical institutions. A total of 123 patients with moderately active UC received 4\u00a0g/day (two divided doses) versus 2.25\u00a0g/day (three divided doses) for 8\u00a0weeks. Primary endpoint was the ulcerative colitis-disease activity index (UC-DAI) score before and after 8\u00a0weeks of treatment. The improvement of each individual UC-DAI variable, remission, and efficacy rates were secondary endpoints. Safety was determined by laboratory data, vital signs, subjective symptoms, and objective findings.ResultsPatients receiving 4\u00a0g/day achieved a change in UC-DAI score significantly superior to those receiving 2.25\u00a0g/day [\u22123.0 (95% confidence intervals (CI) \u22123.8 to \u22122.3) vs. \u22120.8 (95% CI \u22121.8 to 0.1), respectively]. There were significant differences in all UC-DAI variables between the groups. Remission rates were 22.0% (4\u00a0g/day) and 15.3% (2.25\u00a0g/day). The efficacy rate was significantly better with 4 versus 2.25\u00a0g/day [76.3 vs. 45.8%, respectively (95% CI 13.8\u201347.2); P\u00a0=\u00a00.001]. No difference was seen in adverse events or adverse drug reactions.ConclusionsA dose of 4\u00a0g/day was significantly superior to 2.25\u00a0g/day in terms of UC-DAI score for patients with moderately active UC. Safety profiles were similar for both doses.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00535-010-0308-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1009747", 
        "issn": [
          "0944-1174", 
          "1435-5922"
        ], 
        "name": "Journal of Gastroenterology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "46"
      }
    ], 
    "keywords": [
      "active ulcerative colitis", 
      "Ulcerative Colitis Disease Activity Index", 
      "UC-DAI score", 
      "ulcerative colitis", 
      "efficacy rate", 
      "parallel-group clinical study", 
      "Colitis Disease Activity Index", 
      "parallel-dose study", 
      "weeks of treatment", 
      "adverse drug reactions", 
      "Japanese medical institutions", 
      "MethodsA multicenter", 
      "ConclusionsA dose", 
      "Secondary endpoints", 
      "primary endpoint", 
      "remission rate", 
      "adverse events", 
      "induction dose", 
      "safety profile", 
      "mesalazine formulations", 
      "subjective symptoms", 
      "drug reactions", 
      "objective findings", 
      "clinical studies", 
      "oral preparations", 
      "patients", 
      "vital signs", 
      "activity index", 
      "laboratory data", 
      "colitis", 
      "significant differences", 
      "mesalazine", 
      "medical institutions", 
      "dose", 
      "days", 
      "weeks", 
      "endpoint", 
      "treatment", 
      "scores", 
      "safety", 
      "multicenter", 
      "remission", 
      "ResultsPatients", 
      "symptoms", 
      "doses", 
      "efficacy", 
      "rate", 
      "differences", 
      "total", 
      "study", 
      "signs", 
      "group", 
      "findings", 
      "index", 
      "variables", 
      "background", 
      "events", 
      "effect", 
      "improvement", 
      "changes", 
      "profile", 
      "institutions", 
      "data", 
      "preparation", 
      "reaction", 
      "formulation", 
      "terms", 
      "aimsOral mesalazine formulations", 
      "individual UC-DAI variable", 
      "UC-DAI variable", 
      "phase III parallel-dosing study", 
      "III parallel-dosing study"
    ], 
    "name": "Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study", 
    "pagination": "46-56", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004696828"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00535-010-0308-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20878425"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00535-010-0308-3", 
      "https://app.dimensions.ai/details/publication/pub.1004696828"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_509.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00535-010-0308-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00535-010-0308-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00535-010-0308-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00535-010-0308-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00535-010-0308-3'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      22 PREDICATES      117 URIs      106 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00535-010-0308-3 schema:about N02a44fbc73de441bbd513ff334248c1c
2 N0579d5d378e845c8aeb83af46f7c22f5
3 N29812c0c85d64c10bbdd1b1c7d9bf699
4 N3823a437a0e545dd8983bc8abe81d9f3
5 N3c5412a9536141e6b9c3128a925fc8ed
6 N49eea70aea824d42b1b984c768e770d9
7 N58705b9bdad3468fae66343d0dc6e809
8 N896e7c76aeb7461b911a303e1d8634cb
9 N994f8c82b7764e3899ce99abc12ad054
10 Nacfa9972c256478482df5fba4cfd3afe
11 Nc2d718af48714331a865173671b48f8c
12 Nce463ed48e7147d08ab6ef3ec1ea7619
13 Ncfdc839daee74952a117b6950a1ac3fb
14 Nd292de4990c34a0a88464b58312cf5ab
15 Ne5f4fa5116104edd9686a10d25a3896d
16 Nf6c77927d61f405f9b1993ea86852e66
17 anzsrc-for:11
18 anzsrc-for:1115
19 schema:author N2c75f8edf0cb4ea5a0a408ba7003b0d1
20 schema:citation sg:pub.10.1038/ajg.2009.727
21 sg:pub.10.1111/j.1572-0241.2004.40036.x
22 sg:pub.10.1111/j.1572-0241.2005.00248.x
23 schema:datePublished 2010-09-29
24 schema:datePublishedReg 2010-09-29
25 schema:description Background and aimsOral mesalazine formulations are effective in the treatment of active ulcerative colitis (UC). It is not clear what induction dose of mesalazine is optimal for treating patients with active UC. We aimed to evaluate the efficacy and safety of 4 versus 2.25 g/day for selected patients with active UC.MethodsA multicenter, randomized, double-blind, parallel-group clinical study in 39 Japanese medical institutions. A total of 123 patients with moderately active UC received 4 g/day (two divided doses) versus 2.25 g/day (three divided doses) for 8 weeks. Primary endpoint was the ulcerative colitis-disease activity index (UC-DAI) score before and after 8 weeks of treatment. The improvement of each individual UC-DAI variable, remission, and efficacy rates were secondary endpoints. Safety was determined by laboratory data, vital signs, subjective symptoms, and objective findings.ResultsPatients receiving 4 g/day achieved a change in UC-DAI score significantly superior to those receiving 2.25 g/day [−3.0 (95% confidence intervals (CI) −3.8 to −2.3) vs. −0.8 (95% CI −1.8 to 0.1), respectively]. There were significant differences in all UC-DAI variables between the groups. Remission rates were 22.0% (4 g/day) and 15.3% (2.25 g/day). The efficacy rate was significantly better with 4 versus 2.25 g/day [76.3 vs. 45.8%, respectively (95% CI 13.8–47.2); P = 0.001]. No difference was seen in adverse events or adverse drug reactions.ConclusionsA dose of 4 g/day was significantly superior to 2.25 g/day in terms of UC-DAI score for patients with moderately active UC. Safety profiles were similar for both doses.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf Nb83e7cc592df4f6287be8e3c0ef22550
30 Nd0c0d37a439d424ab939b4960d066461
31 sg:journal.1009747
32 schema:keywords Colitis Disease Activity Index
33 ConclusionsA dose
34 III parallel-dosing study
35 Japanese medical institutions
36 MethodsA multicenter
37 ResultsPatients
38 Secondary endpoints
39 UC-DAI score
40 UC-DAI variable
41 Ulcerative Colitis Disease Activity Index
42 active ulcerative colitis
43 activity index
44 adverse drug reactions
45 adverse events
46 aimsOral mesalazine formulations
47 background
48 changes
49 clinical studies
50 colitis
51 data
52 days
53 differences
54 dose
55 doses
56 drug reactions
57 effect
58 efficacy
59 efficacy rate
60 endpoint
61 events
62 findings
63 formulation
64 group
65 improvement
66 index
67 individual UC-DAI variable
68 induction dose
69 institutions
70 laboratory data
71 medical institutions
72 mesalazine
73 mesalazine formulations
74 multicenter
75 objective findings
76 oral preparations
77 parallel-dose study
78 parallel-group clinical study
79 patients
80 phase III parallel-dosing study
81 preparation
82 primary endpoint
83 profile
84 rate
85 reaction
86 remission
87 remission rate
88 safety
89 safety profile
90 scores
91 significant differences
92 signs
93 study
94 subjective symptoms
95 symptoms
96 terms
97 total
98 treatment
99 ulcerative colitis
100 variables
101 vital signs
102 weeks
103 weeks of treatment
104 schema:name Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study
105 schema:pagination 46-56
106 schema:productId N0ba798435a3c4a00a7b1092412c05d9c
107 N63a5160f3a564c51a1f3498ca4bdde00
108 Nd64259e9e73e4533a14852e4f9285e00
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004696828
110 https://doi.org/10.1007/s00535-010-0308-3
111 schema:sdDatePublished 2021-11-01T18:14
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N1333496fd8844844a972bdc2b2fb5031
114 schema:url https://doi.org/10.1007/s00535-010-0308-3
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N01a83bdac59c4493aad10cc34c487901 rdf:first sg:person.01233517271.71
119 rdf:rest Nb42935631a704f658011faf0619ae50e
120 N02a44fbc73de441bbd513ff334248c1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Adolescent
122 rdf:type schema:DefinedTerm
123 N0579d5d378e845c8aeb83af46f7c22f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Dose-Response Relationship, Drug
125 rdf:type schema:DefinedTerm
126 N0ba798435a3c4a00a7b1092412c05d9c schema:name doi
127 schema:value 10.1007/s00535-010-0308-3
128 rdf:type schema:PropertyValue
129 N1333496fd8844844a972bdc2b2fb5031 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N29812c0c85d64c10bbdd1b1c7d9bf699 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Male
133 rdf:type schema:DefinedTerm
134 N2c75f8edf0cb4ea5a0a408ba7003b0d1 rdf:first sg:person.0650711113.80
135 rdf:rest Na53aae2e16514aebae9833f66e0605fd
136 N3823a437a0e545dd8983bc8abe81d9f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Severity of Illness Index
138 rdf:type schema:DefinedTerm
139 N3c1be82a6e554f3c984b68d699c1e8a9 rdf:first sg:person.01146640377.43
140 rdf:rest rdf:nil
141 N3c5412a9536141e6b9c3128a925fc8ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Double-Blind Method
143 rdf:type schema:DefinedTerm
144 N49eea70aea824d42b1b984c768e770d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Colitis, Ulcerative
146 rdf:type schema:DefinedTerm
147 N58705b9bdad3468fae66343d0dc6e809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Adult
149 rdf:type schema:DefinedTerm
150 N63a5160f3a564c51a1f3498ca4bdde00 schema:name pubmed_id
151 schema:value 20878425
152 rdf:type schema:PropertyValue
153 N896e7c76aeb7461b911a303e1d8634cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 N994f8c82b7764e3899ce99abc12ad054 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Drug Administration Schedule
158 rdf:type schema:DefinedTerm
159 Na53aae2e16514aebae9833f66e0605fd rdf:first sg:person.011447440744.16
160 rdf:rest N01a83bdac59c4493aad10cc34c487901
161 Nacfa9972c256478482df5fba4cfd3afe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Treatment Outcome
163 rdf:type schema:DefinedTerm
164 Nb42935631a704f658011faf0619ae50e rdf:first sg:person.0711674512.56
165 rdf:rest N3c1be82a6e554f3c984b68d699c1e8a9
166 Nb83e7cc592df4f6287be8e3c0ef22550 schema:issueNumber 1
167 rdf:type schema:PublicationIssue
168 Nc2d718af48714331a865173671b48f8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Female
170 rdf:type schema:DefinedTerm
171 Nce463ed48e7147d08ab6ef3ec1ea7619 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Middle Aged
173 rdf:type schema:DefinedTerm
174 Ncfdc839daee74952a117b6950a1ac3fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Young Adult
176 rdf:type schema:DefinedTerm
177 Nd0c0d37a439d424ab939b4960d066461 schema:volumeNumber 46
178 rdf:type schema:PublicationVolume
179 Nd292de4990c34a0a88464b58312cf5ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Mesalamine
181 rdf:type schema:DefinedTerm
182 Nd64259e9e73e4533a14852e4f9285e00 schema:name dimensions_id
183 schema:value pub.1004696828
184 rdf:type schema:PropertyValue
185 Ne5f4fa5116104edd9686a10d25a3896d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Anti-Inflammatory Agents, Non-Steroidal
187 rdf:type schema:DefinedTerm
188 Nf6c77927d61f405f9b1993ea86852e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Tablets
190 rdf:type schema:DefinedTerm
191 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
192 schema:name Medical and Health Sciences
193 rdf:type schema:DefinedTerm
194 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
195 schema:name Pharmacology and Pharmaceutical Sciences
196 rdf:type schema:DefinedTerm
197 sg:journal.1009747 schema:issn 0944-1174
198 1435-5922
199 schema:name Journal of Gastroenterology
200 schema:publisher Springer Nature
201 rdf:type schema:Periodical
202 sg:person.011447440744.16 schema:affiliation grid-institutes:grid.265050.4
203 schema:familyName Suzuki
204 schema:givenName Yasuo
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011447440744.16
206 rdf:type schema:Person
207 sg:person.01146640377.43 schema:affiliation grid-institutes:grid.26091.3c
208 schema:familyName Hibi
209 schema:givenName Toshifumi
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146640377.43
211 rdf:type schema:Person
212 sg:person.01233517271.71 schema:affiliation grid-institutes:grid.410781.b
213 schema:familyName Mitsuyama
214 schema:givenName Keiichi
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233517271.71
216 rdf:type schema:Person
217 sg:person.0650711113.80 schema:affiliation grid-institutes:grid.414859.5
218 schema:familyName Hiwatashi
219 schema:givenName Nobuo
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650711113.80
221 rdf:type schema:Person
222 sg:person.0711674512.56 schema:affiliation grid-institutes:grid.257016.7
223 schema:familyName Munakata
224 schema:givenName Akihiro
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711674512.56
226 rdf:type schema:Person
227 sg:pub.10.1038/ajg.2009.727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021345588
228 https://doi.org/10.1038/ajg.2009.727
229 rdf:type schema:CreativeWork
230 sg:pub.10.1111/j.1572-0241.2004.40036.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003586589
231 https://doi.org/10.1111/j.1572-0241.2004.40036.x
232 rdf:type schema:CreativeWork
233 sg:pub.10.1111/j.1572-0241.2005.00248.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022975557
234 https://doi.org/10.1111/j.1572-0241.2005.00248.x
235 rdf:type schema:CreativeWork
236 grid-institutes:grid.257016.7 schema:alternateName First Division of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan
237 schema:name First Division of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan
238 rdf:type schema:Organization
239 grid-institutes:grid.26091.3c schema:alternateName Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku, 160-8582, Tokyo, Japan
240 schema:name Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku, 160-8582, Tokyo, Japan
241 rdf:type schema:Organization
242 grid-institutes:grid.265050.4 schema:alternateName Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, 285-8741, Sakura, Chiba, Japan
243 schema:name Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, 285-8741, Sakura, Chiba, Japan
244 rdf:type schema:Organization
245 grid-institutes:grid.410781.b schema:alternateName Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
246 schema:name Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
247 rdf:type schema:Organization
248 grid-institutes:grid.414859.5 schema:alternateName Department of Gastroenterology, Iwaki Kyoritsu General Hospital, 16 Kusehara, Mimayamachi, Uchigo, 973-8555, Iwaki, Japan
249 schema:name Department of Gastroenterology, Iwaki Kyoritsu General Hospital, 16 Kusehara, Mimayamachi, Uchigo, 973-8555, Iwaki, Japan
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...